Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10 microgram hepatitis B vaccine plus different HBIG doses for prevention of mother-to-child HBV transmission
ChiCTR-PRC-12002790Phase 4Completed
- Sponsor
- Chinese Center for Disease Control and Prevention
- Start
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant hepatitis B vaccine Bio Farma and hepatitis B immune globulin in hepatitis B (HBV) (2 arms), sponsored by Chinese Center for Disease Control and Prevention. Primary endpoints: HBsAg, anti-HBs and 4 more. Started Jan 2012; status: completed.
02
Drugs
recombinant hepatitis B vaccine Bio Farmahepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-PRC-12002790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-12002790.